Eli Lilly And Co (LLY) Shares Sold by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC lowered its position in shares of Eli Lilly And Co (NYSE:LLY) by 17.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,950 shares of the company’s stock after selling 1,300 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Eli Lilly And Co were worth $460,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Avestar Capital LLC acquired a new position in Eli Lilly And Co in the 4th quarter valued at about $100,000. Gradient Investments LLC acquired a new position in Eli Lilly And Co in the 4th quarter valued at about $103,000. Stelac Advisory Services LLC acquired a new position in Eli Lilly And Co in the 1st quarter valued at about $134,000. Silvant Capital Management LLC acquired a new position in Eli Lilly And Co in the 1st quarter valued at about $150,000. Finally, Truewealth LLC acquired a new position in Eli Lilly And Co in the 4th quarter valued at about $186,000. Institutional investors and hedge funds own 76.09% of the company’s stock.

LLY has been the topic of several recent research reports. Jefferies Financial Group set a $90.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research report on Friday, April 13th. Credit Suisse Group set a $80.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research report on Sunday, April 22nd. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Wednesday, May 23rd. JPMorgan Chase & Co. set a $105.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, ValuEngine cut Eli Lilly And Co from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $93.89.

NYSE LLY opened at $85.72 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.01 and a current ratio of 1.41. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a market cap of $93.20 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.45 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.21. Eli Lilly And Co had a return on equity of 35.37% and a net margin of 4.82%. The company had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.51 billion. During the same quarter in the previous year, the firm posted $0.98 EPS. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. equities research analysts forecast that Eli Lilly And Co will post 5.15 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 8th. Shareholders of record on Thursday, May 17th were given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.62%. The ex-dividend date of this dividend was Wednesday, May 16th. Eli Lilly And Co’s payout ratio is 52.57%.

In other news, major shareholder Lilly Endowment Inc sold 51,198 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $86.38, for a total transaction of $4,422,483.24. Following the sale, the insider now owns 122,349,606 shares of the company’s stock, valued at approximately $10,568,558,966.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua L. Smiley sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $79.20, for a total value of $237,600.00. Following the sale, the chief financial officer now directly owns 20,029 shares in the company, valued at approximately $1,586,296.80. The disclosure for this sale can be found here. Insiders have sold a total of 799,360 shares of company stock worth $66,431,613 in the last quarter. 0.11% of the stock is currently owned by insiders.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit